Skip to content
OpenCapital
Get started

Biogen BIIB VUMERITY — Total Revenue

Other product segments

TYSABRI
$441.5M+15.7%
SPINRAZA
$374M-11.8%
AVONEX
$163.2M-2.2%
SKYCLARYS
$150.7M+21.6%
BENEPALI
$122.1M+9.7%
TECFIDERA
$109.5M-46.9%
PLEGRIDY
$64.3M+8.1%
ZURZUVAE
$55.4M+100%
IMRALDI
$49.6M+4.6%
QALSODY
$32.5M+110%
FLIXABI
$10.5M-19.8%
BYOOVIZ
$0-100%
FAMPYRA
$0-100%
FUMADERM And ADUHELM
$0-100%
TOFIDENCE
$0-100%

Similar metrics at other companies

Organon logo
OGNVtama — Revenue
$25M+4.2%
Gilead Sciences logo
GILDVeklury — Total revenues
$144M-52.3%
Gilead Sciences logo
GILDVemlidy — Total revenues
$237M-6.0%
BioMarin Pharmaceuticals logo
BMRNVIMIZIM — Total revenues
$210.2M+11.6%
Alkermes logo
ALKSVumerity — Percentage Of Net Sales In Royalty Payment
3.8%0.0pp
Pfizer logo
PFETotal Revenue
$14.45B+5.4%

Other financials

Income statement

See full
Revenue$2.5B+1.9%
Gross profit$1.8B+0.8%
Operating income$610.7M—
Net income$319.5M+32.8%
EPS (diluted)$2.15+31.1%

Balance sheet

See full
Cash & equivalents$3.4B+30.2%
Total debt$6.6B+34.7%
Total equity$18.7B+9.9%
Total assets$29.5B+5.2%

Cash flow

See full
Operating cash flow$645.5M+149%
CapEx$51.2M+38.0%
Free cash flow$594.3M+167%

Valuation

See full
Market cap$31.89B+72.3%
Enterprise value$35.07B+57.0%
P/E22.5×+10.4×
P/S3.2×+1.4×

Profitability

See full
Gross margin75.5%-0.1pp
Operating margin22.9%—
Net margin14.3%-0.8pp
FCF margin24.4%-0.4pp

Returns & leverage

See full
Return on equity8%-1.2pp
Debt / equity0.4×+0.1×
Current ratio3.1×+1.6×

Where this comes from

Reported directly by Biogen in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Biogen’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biogen's vumerity — total revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biogen's VUMERITY — total revenue?
Biogen (BIIB) reported VUMERITY — total revenue of $179M in Q1 2026.
How has Biogen's VUMERITY — total revenue changed year-over-year?
Biogen's VUMERITY — total revenue increased by 29.0% year-over-year, from $138.8M to $179M.
What is the long-term trend for Biogen's VUMERITY — total revenue?
Over 4 years (2021 to 2025), Biogen's VUMERITY — total revenue has grown at a 16.1% compound annual growth rate (CAGR), from $410.4M to $746.8M.
What does VUMERITY — total revenue mean?
This metric represents the total gross revenue generated from the sale of a specific pharmaceutical product within the company's portfolio. It reflects the market demand and commercial success of the therapy in treating its indicated condition. Monitoring this figure helps assess the product's lifecycle stage and its contribution to the company's overall top-line growth.